secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pacira BioSciences, Inc. (PCRX)
CIK:        0001396814
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001396814-22-000070
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pacira reports Oct 2022 preliminary net sales of $54.9M; EXPAREL average daily sales 106% of prior year
--------------------------------------------------------------------------------

- Preliminary unaudited net product sales of $54.9M for October 2022.
- EXPAREL net sales $45.0M (vs $42.5M Oct 2021); average daily sales 106% of prior year.
- ZILRETTA net sales $8.6M (acquired Nov 2021); iovera° net sales $1.3M (vs $1.2M).
- Company not providing FY2022 revenue/gross margin guidance due to COVID-19 uncertainty.
- CEO Dave Stack reiterates confidence in double-digit growth and value creation from partnerships.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1396814/000139681422000070/0001396814-22-000070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1396814/000139681422000070/pcrx-20221114.htm
  HTML page:      https://secwatch.observer/filing/0001396814-22-000070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer